SNIPR Biome
SNIPR Biome is pioneering CRISPR-based microbial gene therapy with a focus on engineering microbiomes to treat serious and life-threatening diseases. The company aims to revolutionize disease management through precision killing of bacteria, impacting conditions like IBD, multi-drug resistant infections, and cancer. Since its inception in August 2017, SNIPR Biome has raised $50M in Series A funding, grown to a team of over 30 scientists, and holds several patents. The company is based in Copenhagen, Denmark, and is committed to developing microbiome drugs for clinical trials.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Pipeline of CRISPR-based microbiome therapeutics (unnamed programs)
Preclinical and translational therapeutic programs that use CRISPR-based approaches to modulate the gut microbiome for treatment of diseases influenced by microbiota.
Pipeline of CRISPR-based microbiome therapeutics (unnamed programs)
Preclinical and translational therapeutic programs that use CRISPR-based approaches to modulate the gut microbiome for treatment of diseases influenced by microbiota.
Services
Collaborative partnerships for co-development, licensing, or research alliances focused on microbiome-targeted therapeutics.
Collaborative partnerships for co-development, licensing, or research alliances focused on microbiome-targeted therapeutics.
Expertise Areas
- CRISPR-based microbiome therapeutics
- Microbiome engineering and modulation
- Targeted antimicrobial strategies
- Preclinical to first-in-human clinical development
Key Technologies
- CRISPR gene editing
- CRISPR-guided delivery vectors for microbes
- Microbiome modulation techniques
- Targeted bactericidal constructs
News & Updates
SNIPR Biome received funding to develop CRISPR-medicines targeting EED in pregnant women.
Series A Funding
Raised $50M in Series A funding to advance CRISPR-based microbiome drugs to human clinical trials.
Team Growth
Since 2017, the team has grown to over 30 PhD scientists.
Patents
Holds several patents, with over 30 granted US patents.
Recognition
Received recognition such as the EY Entrepreneur Of The Year award.
SNIPR Biome received funding to develop CRISPR-medicines targeting EED in pregnant women.
Series A Funding
Raised $50M in Series A funding to advance CRISPR-based microbiome drugs to human clinical trials.
Team Growth
Since 2017, the team has grown to over 30 PhD scientists.
Patents
Holds several patents, with over 30 granted US patents.
Recognition
Received recognition such as the EY Entrepreneur Of The Year award.